The conjugation of antibodies on NP is versatile, and a variety of antibodies have been used to achieve specific experimental objectives, such as the use of antibodies targeting the vascular endothelial growth factor receptor (i.e., to block tumor angiogenesis) [12], matrix metalloproteinases (i.e., to block tumor invasion) [14], and transferrin receptor (i.e., to facilitate the crossing of NP through the blood-brain barrier) [15]. This evidence concerns the gene TFRC and neoplasm.